Glyco-biomarker Ceruloplasmin (CP) Detection Service

Glyco-biomarker Ceruloplasmin (CP) Detection Service

Ceruloplasmin (CP) is a protein ferroxidase that plays many important functional roles. CD BioGlyco provides a variety of strategies for CP detection services to assist investigators in the diagnosis of Wilson disease as well as other diseases related to the liver, gallbladder, and kidney. We are confident to accelerate the progress of your research in the field of glycoproteomics.


CP is a blue glycoprotein that contains six copper ions in each molecule. The liver binds copper to a protein to generate CP and then releases it into the bloodstream, where about 95% of the copper is bound to CP. Copper is introduced into the molecule when it is synthesized by hepatocytes and released when CP is catabolized. CP plays a significant role in iron metabolism and copper transport and is also an indicator of the health status of dairy cows. Besides copper transport, CP also catalyzes the oxidation of iron, catecholamines, polyphenols and polyamines.

Currently, analytical procedures used to determine CP include immunoturbidimetry and nephelometry assays. The most important clinical application of CP analysis is the detection of Wilson disease, a rare genetic disorder associated with excess copper storage in the liver, cornea, brain and kidneys, and with reduced levels of CP. Moreover, CP is a sensitive acute-phase reactant that increases during acute and chronic inflammation processes, and large increases result in a green-blue coloration of the sera.

The principle of  the one-step simultaneous detection of CuEXC and CP in human serum. Fig.1 The principle of the one-step simultaneous detection of CuEXC and CP in human serum. (Xiong, 2019)


Combining extensive expertise, CD BioGlyco has established a variety of convenient methods for detecting CP in urine and serum samples. The techniques we provide include but are not limited to:

  • We detect CP content using immunonephelometry, which has high sensitivity and specificity and has been widely used in clinical.
  • We employ an immunoaffinity chromatography and size-exclusion chromatography (SEC)-inductively coupled plasma mass spectrometry (ICP-MS) method for the determination of CP in human serum. A combination of immunoaffinity and SEC is used to separate CP from other proteins and inorganic ions, and ICP-MS was used to detect 63Cu and 65Cu to identify the protein.
  • We employ a simple one-step competitive immunoassay based on antigen-coated magnetic nanoparticles (Immuno-MNPs) and antibody-functionalized quantum dots (QDs-Abs) for the rapid detection of CP.


  • Diagnosis of Wilson disease
  • Evaluation and management of copper-related diseases
  • Prediction of acute diseases

Advantages of Us

  • Reliable and accurate experimental results
  • Professional technical teams
  • Many years of experience in terms of glycoproteomics
  • Time-saving and cost-effective

At CD BioGlyco, we have developed various methods capable of accurate and reproducible CP measurements and have determined the accuracy and precision of the methods using CP-certified reference serum. If you have a demand for glyco-biomarker detection services, please free to contact us.


  1. Xiong, Y.; et al. Rapid laboratory diagnosis of Wilson's disease: One-step simultaneous detection of exchangeable copper and ceruloplasmin in serum based on nanotechnology. Sensors & Actuators. 2019, B281(FEB.):713-719.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.